Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions: Danicopan, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 17 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more

Conditions: COVID-19-Induced Parosmia
Interventions: Stellate Ganglion Block, Placebo Sham Injection; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: COVID-19
Interventions: SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Chronic Post-traumatic Headache
Interventions: Rizatriptan, Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 49 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more

Conditions: Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
Interventions: mifepristone, placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 22 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 42
States / cities: Little Rock, Arkansas • Anaheim, California • Downey, California + 34 more

Conditions: Ischemic Heart Disease
Interventions: Quinapril, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Tobacco Use Disorder, Smoking Cessation
Interventions: Lorcaserin Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: The Mind Research Network; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide); Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
Interventions: sepofarsen, Placebo IVT; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 6 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more

Conditions: Hypoxic Ischemic Encephalopathy
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 24 Hours
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Albuquerque, New Mexico • Nashville, Tennessee • Ogden, Utah + 3 more

Conditions: PTSD, Sleep Disorders
Interventions: prazosin, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Loma Linda, California • Long Beach, California • Palo Alto, California + 12 more

Conditions: Malignant Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more

Conditions: Obesity
Interventions: ACCG-2671, Placebo; Drug
Lead sponsor: Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Cypress, California • Lake Forest, California • Decatur, Georgia + 3 more

Conditions: Muscular Atrophy, Spinal
Interventions: Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Palo Alto, California • New York, New York

Conditions: Chronic Migraine
Interventions: onabotulinumtoxinA, Topiramate, Placebo; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Hepatocellular Carcinoma
Interventions: TheraBionic Device, Placebo Device, Quality of Life Assessment; Device
Lead sponsor: THERABIONIC INC.; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Tampa, Florida • Chicago, Illinois • Winston-Salem, North Carolina + 4 more

Conditions: Pain
Interventions: Ketamine 0.15mg/kg, Ketamine 0.3mg/kg, Placebo; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more

Conditions: Multiple Sclerosis
Interventions: Cladribine, Placebo, Rebif® new formulation (RNF); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more

Conditions: Cataract
Interventions: Clobetasol Propionate, Vehicle; Drug
Lead sponsor: Salvat; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Sun City, Arizona • Hemet, California • Inglewood, California + 15 more

Conditions: Schizophrenia
Interventions: RISPERDAL CONSTA, Paliperidone palmitate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 1,221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more

Conditions: Heart Failure
Interventions: Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Search by objective public record fields.

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Stellate Ganglion Block for COVID-induced Parosmia

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia

Mechanisms of Lorcaserin for Smoking Cessation

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Darbe Administration in Newborns Undergoing Cooling for Encephalopathy

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma

Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Oral Cladribine in Early Multiple Sclerosis (MS)

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)